OncoMatch/Clinical Trials/NCT05941741
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
Is NCT05941741 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Immune checkpoint inhibitor and Chemotherapy for nasopharyngeal carcinoma.
Treatment: Chemotherapy · Immune checkpoint inhibitor — This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients. The purpose of this study is to evaluate the efficacy of induction chemotherapy (IC) combined with low-dose radiation and immune checkpoint inhibitor (ICI) followed by concurrent chemoradiotherapy (CCRT) versus IC+CCRT, and compare the treatment-related adverse events and quality of life in two groups.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage T4N1M0, T1-4N2-3M0
Excluded: Stage DISTANT METASTASES
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
Not received radiotherapy
Cannot have received: chemotherapy
Not received...chemotherapy
Cannot have received: immunotherapy
Not received...immunotherapy
Cannot have received: other anti-tumor treatment
Not received...other anti-tumor treatment
Lab requirements
Blood counts
white blood cell count ≥ 4×109/l, neutrophile granulocyte count ≥ 1.5×109/l, hemoglobin ≥ 9g/l, platelet count ≥ 100×109/l
Kidney function
blood urea nitrogen or creatinine ≤ 1.5×upper limit of normal or endogenous creatinine clearance ≥ 60ml/min (cockcroft-gault formula)
Liver function
alanine aminotransferase or aspartate aminotransferase < 2.5×upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify